» Articles » PMID: 33417258

Antagonistic Effects of Finerenone and Spironolactone on the Aldosterone-regulated Transcriptome of Human Kidney Cells

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 2021 Jan 8
PMID 33417258
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Aldosterone, the main mineralocorticoid hormone in humans, plays a pivotal role in the control of water and salt reabsorption via activation of the mineralocorticoid receptor (MR). Alterations in MR signaling pathway lead to renal dysfunction, including chronic kidney disease and renal fibrosis, that can be prevented or treated with mineralocorticoid receptor antagonists (MRAs). Here, we used RNA-Sequencing to analyze effects of two MRAs, spironolactone and finerenone, on the aldosterone-induced transcriptome of a human renal cell line stably expressing the MR. Bioinformatics analysis of the data set reveals the identity of hundreds of genes induced or repressed by aldosterone. Their regulation is modulated in a time-dependent manner and, for the induced genes, depends on the aldosterone-driven direct binding of the MR onto its genomic targets that we have previously characterized. Although both MRAs block aldosterone-induced as well as aldosterone-repressed genes qualitatively similarly, finerenone has a quantitatively more efficient antagonism on some aldosterone-induced genes. Our data provide the first complete transcriptome for aldosterone on a human renal cell line and identifies pro-inflammatory markers (IL6, IL11, CCL7, and CXCL8) as aldosterone-repressed genes.

Citing Articles

Finerenone in Heart Failure-A Novel Therapeutic Approach.

Holst-Hansen A, Grimm D, Wehland M Int J Mol Sci. 2025; 25(24.

PMID: 39769473 PMC: 11678263. DOI: 10.3390/ijms252413711.


A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist.

Zhai S, Ma B, Chen W, Zhao Q Front Cardiovasc Med. 2024; 11:1476029.

PMID: 39376623 PMC: 11456546. DOI: 10.3389/fcvm.2024.1476029.


Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models.

Varda L, Ekart R, Lainscak M, Maver U, Bevc S Int J Mol Sci. 2024; 25(16).

PMID: 39201774 PMC: 11354261. DOI: 10.3390/ijms25169088.


Control of sodium appetite by hindbrain aldosterone-sensitive neurons.

Kuralay A, McDonough M, Resch J Mol Cell Endocrinol. 2024; 592:112323.

PMID: 38936597 PMC: 11381173. DOI: 10.1016/j.mce.2024.112323.


The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances.

Chen X, Li X, Zhang K, Lian K, Zhang W, Song Y Clin Exp Nephrol. 2023; 28(2):125-135.

PMID: 37847437 DOI: 10.1007/s10157-023-02413-2.